The Women’s Tennis Association (WTA) will require all players to undergo a one-time genetic sex test to compete on the WTA Tour under a new eligibility policy that takes effect on Tuesday.
Under the updated regulations, players must provide a cheek swab, blood or saliva sample to determine the presence of the SRY gene, a gene located on the Y chromosome that is associated with male biological development.
Only players who return a negative result, indicating no presence of the SRY gene, will be eligible to compete on the women’s professional tour. Players who test positive will undergo further medical assessment before a decision is made on their eligibility.
New policy replaces testosterone-based rule
The updated policy replaces the WTA’s previous eligibility framework, last revised in 2024, which allowed transgender women to compete if they had maintained testosterone levels below 2.5 nanomoles per litre (nmol/L) continuously for at least two years.
The WTA said there are currently no known transgender women competing on the WTA Tour.
ALSO READ: 2025: Female tennis players faced 12,000 abusive social media posts – Report
Players will only be required to undergo the genetic test once during their lifetime. They must also sign a declaration acknowledging that refusing to comply with the testing process could result in disciplinary action.
Policy aims
In a statement, the governing body said the revised policy was intended to protect competitive fairness while ensuring equal opportunities in women’s tennis.
“The WTA’s women’s eligibility policy is designed to promote equal athletic opportunities in women’s professional tennis and maintain fair competition for all players participating in WTA tournaments,” the organisation said.
The WTA added that the policy had been reviewed following consultations with players and developments across international sport.
“Since first being introduced in 1975, the eligibility policy has undergone periodic review in light of developments across international sport.
“Following the most recent review, which included consultation with WTA members and evolving standards across women’s sport, the WTA board approved an updated WTA women’s eligibility policy beginning in 2026 based on biological sex.”
The organisation also acknowledged the sensitivity of the issue.
“The WTA recognises that this is a sensitive and complex issue and is committed to treating all players with dignity and implementing the policy in a respectful and thoughtful way.”
Wider trend across international sport
The WTA’s decision on genetic sex testing follows similar measures introduced by other international sports federations.
In 2025, World Athletics implemented regulations requiring athletes seeking to compete in the female category at world-ranking competitions to undergo a one-time genetic sex test.
World Boxing also adopted mandatory genetic sex testing in May 2025 for athletes competing in the women’s category.
The WTA’s latest policy aligns women’s professional tennis with a growing number of sports bodies that have shifted from hormone-based eligibility rules to biological sex-based criteria for women’s competitions.
